Related Experiment Videos
Myasthenia gravis after allogeneic bone marrow transplantation
1First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Bone Marrow Transplantation
|July 1, 1994
Summary
Myasthenia gravis can develop after bone marrow transplantation, particularly with chronic graft-versus-host disease. Abruptly stopping immunosuppression may trigger this condition, but treatment for GVHD can resolve symptoms.
Area of Science:
- Hematology
- Immunology
- Neurology
Background:
- Bone marrow transplantation (BMT) is a curative therapy for hematologic malignancies like chronic myeloid leukemia (CML).
- Graft-versus-host disease (GVHD) is a common complication following allogeneic BMT, involving an immune response from donor cells against recipient tissues.
- Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness.
Observation:
- A 37-year-old male with CML developed symptoms of myasthenia gravis, including proximal muscle weakness and bilateral ptosis, 29 months post-BMT.
- These neurological symptoms coincided with an exacerbation of chronic GVHD shortly after the abrupt cessation of immunosuppressive agents (cyclosporine and prednisolone).
Findings:
- Diagnosis of myasthenia gravis was confirmed by clinical presentation and elevated anti-acetylcholine receptor antibody titers.
- All myasthenia gravis symptoms significantly improved upon initiation of treatment for chronic GVHD.
- The patient had chronic GVHD and the HLA B7 haplotype, factors potentially contributing to MG development post-BMT.
Implications:
- This case highlights a potential association between chronic GVHD, immunosuppression withdrawal, and the development of myasthenia gravis after BMT.
- It suggests that managing GVHD effectively might also alleviate associated autoimmune neurological complications.
- Further research is warranted to elucidate the precise mechanisms linking GVHD and myasthenia gravis post-transplantation.